Translation Results Requested Through Conyac Made Public

・Cambodia’s few urban areas are hubs of pharmaceutical consumption.
・Underdeveloped local manufacturing capacities leave the market reliant on imports.
・Consumer perception that foreign-made pharmaceuticals are superior to domestic medicines benefiting foreign drugmakers.
・The country boasts a large number of importers of foreign-made products.

・TheCambodian pharmaceutical market is one of the smallest in the region, as measured on per capita basis.
・Very little foreign manufacturing presence in the country, which has stifled the exposure of the wider market to foreign-made products.
・Poor state of the country’s infrastructure hampers deliveryof healthcare and medicalsupplies, especially to more remote regions ・Counterfeiting is an issue that has detracted some foreign companies from getting involved in the market.
・The lack of a national health insurance system means that the bulk of
pharmaceutical expenditure is sourced from private pockets.
・Low manufacturing costs, potentially attracting some foreign direct investment.
・Some longer term market potential, given the currently underdeveloped nature of the
market and rising population numbers.
・Continued involvement of NGOs in providing essential medicines will represent
points of entry for new players.
・Growing prevalence of chronic lifestyle diseases should see rising pharmaceutical
consumption to treat these conditions. ・Levels of intellectual property protection will remain negatively impacted by the country’s limited funding for medicines, both in the public and private spheres, which will prioritise cheaper, and often counterfeit, products.
・Unless the government shows more concrete measures of its commitment to attracting foreign players, Cambodia will lose out to other locations currently vying to attract multinational investment.
・The absence of a health insurance system to continue hampering wider access to medicines and thus pharmaceutical value development.
・Corruption will remain a major threat to making medicines as well as funding for medicines available through legal channels and to the neediest sectors of society